{"entity":{"id":"idea-prev-glp1-endometrial-hyperplasia","kind":"idea","name":"GLP-1 drugs to reverse endometrial precancer in women with obesity","aka":[],"tldr":"Womb precancer in women with obesity is usually treated with a hormone coil or hysterectomy. Weight-loss drugs might reverse it and protect fertility.","summary":"Womb precancer in women with obesity is usually treated with a hormone coil or hysterectomy, so this idea tests whether adding a GLP-1 receptor agonist to the levonorgestrel intrauterine system reverses atypical endometrial hyperplasia and protects fertility. Obesity drives the condition and a substantial share of cases progress to cancer; weight loss after bariatric surgery reverses hyperplasia, and GLP-1 drugs offer a non-surgical route. The aim is more complete regression and less relapse than the intrauterine system alone. The test is a 300-woman RCT with histological regression at six months as the endpoint. At early-clinical maturity it addresses the bottleneck Prevention we already have is not deployed and links to chemoprevention and endometrial cancer.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)","url":"https://doi.org/10.3322/caac.21440"}],"tags":[],"related":[],"cancers":["endometrial"],"sections":["prevention"],"technologies":["chemoprevention"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-prevention-adoption"],"keyPapers":["paper-islami-ca-cancer-j-clin"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Adding a GLP-1 receptor agonist increases complete regression from about 70% to at least 85% and halves relapse at two years.","rationale":"Weight loss after bariatric surgery reverses hyperplasia; GLP-1 offers a non-surgical route.","test":"300-woman RCT.","maturity":"early-clinical","actor":"research","cost":"medium","horizonYears":3},"route":"/ideas/idea-prev-glp1-endometrial-hyperplasia/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"}],"section":[{"id":"prevention","kind":"section","name":"Prevention & Risk","route":"/fronts/prevention/"}],"technology":[{"id":"chemoprevention","kind":"technology","name":"Chemoprevention & risk-reducing surgery","route":"/technologies/chemoprevention/"},{"id":"glp1-agonists-cancer-risk","kind":"technology","name":"GLP-1 receptor agonists and obesity-related cancer risk","route":"/technologies/glp1-agonists-cancer-risk/"}],"bottleneck":[{"id":"b-prevention-adoption","kind":"bottleneck","name":"Prevention we already have is not deployed","route":"/bottlenecks/b-prevention-adoption/"}],"paper":[{"id":"paper-islami-ca-cancer-j-clin","kind":"paper","name":"Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States","route":"/key-papers/paper-islami-ca-cancer-j-clin/"}],"roadmap":[{"id":"nutrition-lifestyle-roadmap","kind":"roadmap","name":"Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment","route":"/roadmaps/nutrition-lifestyle-roadmap/"}]}}